Mary Johansen

1.7k total citations
43 papers, 1.1k citations indexed

About

Mary Johansen is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Johansen has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Johansen's work include Cancer Treatment and Pharmacology (7 papers), Acute Myeloid Leukemia Research (6 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Mary Johansen is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Acute Myeloid Leukemia Research (6 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Mary Johansen collaborates with scholars based in United States, Japan and United Kingdom. Mary Johansen's co-authors include Timothy Madden, Robert A. Newman, David Ferson, William H. Rosenblatt, Andranik Ovassapian, Irene P. Osborn, Peiying Yang, Samuel J. Hassenbusch, Keith R. Hildebrand and Wallace B. Baze and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Mary Johansen

42 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Johansen United States 16 410 270 261 223 178 43 1.1k
Ru Li China 20 459 1.1× 40 0.1× 105 0.4× 180 0.8× 174 1.0× 67 1.4k
Simon P. Joel United Kingdom 18 828 2.0× 70 0.3× 89 0.3× 483 2.2× 102 0.6× 36 1.5k
Andrew W. Murray Australia 15 301 0.7× 98 0.4× 49 0.2× 38 0.2× 160 0.9× 37 701
Mikinori Torii Japan 18 340 0.8× 16 0.1× 332 1.3× 107 0.5× 76 0.4× 59 1.2k
J.M. Scherrmann France 18 530 1.3× 9 0.0× 93 0.4× 372 1.7× 267 1.5× 53 1.4k
Xiongxiong Pan China 21 726 1.8× 12 0.0× 85 0.3× 166 0.7× 230 1.3× 32 1.5k
Allison J. Janocha United States 20 669 1.6× 18 0.1× 1.1k 4.1× 77 0.3× 134 0.8× 30 2.0k
Yoshihiro Maruo Japan 22 872 2.1× 17 0.1× 422 1.6× 153 0.7× 218 1.2× 96 1.8k
Kathryn Sangster United Kingdom 13 279 0.7× 11 0.0× 37 0.1× 225 1.0× 98 0.6× 26 766
Danchen Wu Canada 20 856 2.1× 10 0.0× 739 2.8× 51 0.2× 143 0.8× 31 1.6k

Countries citing papers authored by Mary Johansen

Since Specialization
Citations

This map shows the geographic impact of Mary Johansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Johansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Johansen more than expected).

Fields of papers citing papers by Mary Johansen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Johansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Johansen. The network helps show where Mary Johansen may publish in the future.

Co-authorship network of co-authors of Mary Johansen

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Johansen. A scholar is included among the top collaborators of Mary Johansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Johansen. Mary Johansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Levis, Mark J., Alexander E. Perl, Gary J. Schiller, et al.. (2024). A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Advances. 8(10). 2527–2535. 9 indexed citations
2.
Langer, Corey J., Brendan D. Curti, Charles M. Farber, et al.. (2024). A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2615–2615. 2 indexed citations
3.
Jankú, Filip, Milind Javle, Shiraj Sen, et al.. (2023). A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors. Cancer. 129(10). 1537–1546. 1 indexed citations
4.
Hong, David S., Haby Henary, G. S. Falchook, et al.. (2014). First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Investigational New Drugs. 32(6). 1204–1212. 58 indexed citations
5.
Frank, Steven J., Mary Johansen, Karen S. Martirosyan, et al.. (2012). A Biodistribution and Toxicity Study of Cobalt Dichloride-N-Acetyl Cysteine in an Implantable MRI Marker for Prostate Cancer Treatment. International Journal of Radiation Oncology*Biology*Physics. 85(4). 1024–1030. 15 indexed citations
6.
Dunn, Denise, He Dong, Peiying Yang, et al.. (2011). In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice‐based stroke models. Journal of Neurochemistry. 119(4). 805–814. 50 indexed citations
7.
Kuttesch, John F., Mark Krailo, Timothy Madden, Mary Johansen, & Archie Bleyer. (2009). Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group study. Pediatric Blood & Cancer. 53(4). 590–593. 40 indexed citations
8.
Golemović, Mirna, Alfonso Quintás‐Cardama, Taghi Manshouri, et al.. (2009). MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells. Investigational New Drugs. 28(4). 402–412. 13 indexed citations
9.
Fokt, Izabela, et al.. (2008). 2-Deoxy-2-fluoro-D-mannose induces type II cell death in gliomas.. Cancer Research. 68. 3359–3359. 2 indexed citations
10.
Conrad, Charles A., et al.. (2007). Phase I clinical pharmacokinetics of RTA 744 (berubicin(B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol). Molecular Cancer Therapeutics. 6. 2 indexed citations
11.
Madden, Timothy, Kirk S. Culotta, Nicholas J. Donato, et al.. (2006). The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway. Cancer Research. 66. 1139–1140. 10 indexed citations
12.
Johansen, Mary, et al.. (2004). Continuous Intrathecal Infusion of Hydromorphone: Safety in the Sheep Model and Clinical Implications. Pain Medicine. 5(1). 14–25. 42 indexed citations
13.
Johansen, Mary, et al.. (2002). TREATMENT WITH BOTULINUM TOXIN TYPE B (MYOBLOC) INJECTIONS IN THREE PATIENTS WITH MYOFASCIAL PAIN. Pain Medicine. 3(2). 189.2–189. 1 indexed citations
14.
Johansen, Mary, et al.. (2002). Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models. PubMed. 2(3). 163–173. 9 indexed citations
15.
Ni, Dan, Timothy Madden, Mary Johansen, et al.. (2002). Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander. PubMed. 2(5). 278–285. 34 indexed citations
16.
Margolin, Kim, Jeff Longmate, Timothy W. Synold, et al.. (2001). Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium. Investigational New Drugs. 19(4). 335–340. 63 indexed citations
17.
Johansen, Mary, et al.. (1997). The Use of Microdialysis in Pharmacokinetics and Pharmacodynamics. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(3). 464–481. 72 indexed citations
18.
Ferson, David, Jonathan C. Nesbitt, Garrett L. Walsh, et al.. (1997). The Laryngeal Mask Airway: A New Standard for Airway Evaluation in Thoracic Surgery. The Annals of Thoracic Surgery. 63(3). 768–772. 9 indexed citations
19.
Johansen, Mary, Timothy Madden, Rakesh Mehra, et al.. (1997). Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.. Journal of Clinical Oncology. 15(4). 1481–1491. 23 indexed citations
20.
Wall, Susan M., Mary Johansen, Donald A. Molony, et al.. (1996). Effective clearance of methotrexate using high-flux hemodialysis membranes. American Journal of Kidney Diseases. 28(6). 846–854. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ru Li Breakdown of academic impact, for papers by Simon P. Joel Breakdown of academic impact, for papers by Andrew W. Murray Breakdown of academic impact, for papers by Mikinori Torii Breakdown of academic impact, for papers by J.M. Scherrmann Breakdown of academic impact, for papers by Xiongxiong Pan Breakdown of academic impact, for papers by Allison J. Janocha Breakdown of academic impact, for papers by Yoshihiro Maruo Breakdown of academic impact, for papers by Kathryn Sangster Breakdown of academic impact, for papers by Danchen Wu
Rankless by CCL
2026